NEJM This Week NEJM This Week — June 26, 2025
11 snips
Jun 25, 2025 This week explores groundbreaking findings in treatment for cirrhosis and metastatic colorectal cancer. A study on gene therapy for infantile-onset Pompe disease shows promise, despite some challenges. The discussion on medical education highlights innovative changes and the impact of AI. Attention is drawn to the alarming rise of ultra-processed foods linked to health issues, with a strong plea for better regulation. A poignant case illustrates the systemic failures in healthcare that affect vulnerable individuals, revealing critical gaps in care.
AI Snips
Chapters
Transcript
Episode notes
Limited Benefit of Embolic Protection in TAVI
- Routine use of cerebral embolic protection devices during TAVI does not reduce stroke incidence within 72 hours post-procedure.
- Improvements in valve technology and procedural techniques have lowered stroke rates, limiting device benefit.
Efruxifermin's Limited Impact on Cirrhosis
- Efruxifermin did not significantly reduce fibrosis in compensated cirrhosis due to MASH at 36 weeks.
- Portal hypertension and varied response among patients may explain these negative trial results.
New Effective Therapy for BRAF Colorectal Cancer
- Combination therapy with encorafenib, cetuximab, and chemotherapy improves progression-free and overall survival in BRAF V600E-mutated metastatic colorectal cancer.
- This led to accelerated FDA approval of this treatment as first-line therapy.